GlaxoSmithKline and AstraZeneca will each present clinical trial data on a promising new class of drugs against ovarian cancer as Britain’s top drugmakers compete to burnish their oncology credentials.
AstraZeneca made further headway in a race with competitor GlaxoSmithKline to use a promising new class of drugs to treat ovarian cancer.
GlaxoSmithKline Plc’s cancer treatment Zejula met the main goal of helping patients with ovarian cancer live longer without their disease worsening in a late-stage study, the company said.
Foundation Medicine Inc. received approval from the U.S. Food and Drug Administration for FoundationOne CDx to be used as a companion diagnostic for Lynparza (olaparib) for first-line maintenance therapy in BRCA-mutated advanced ovarian cancer.
ImmunoGen shares fell after the company announced the slashing of 220 employees as part of an effort to reduce ongoing expenses while recovering from an FDA rejection of an ovarian cancer drug.
Lynparza was approved as a first-line maintenance treatment for a type of advanced ovarian cancer by the European Commission.
In GlaxoSmithKline’s first-quarter 2019 report was an announcement that the global pharma giant cut the development of two vaccine programs – one for strep pneumonia and the other for a universal flu vaccine.
Merck KGaA of Darmstadt, Germany and Pfizer Inc. discontinued a Phase III ovarian cancer drug trial after determining that the degree of benefit observed in the treatment during an interim analysis does not support the continuation of the study.
SOTIO presented results from SOV02, the biotechnology company’s Phase II clinical trial evaluating DCVAC/OvCa – an active cellular immunotherapy product – in patients with recurrent ovarian cancer at 2019 SGO’s 50th Annual Meeting on Women’s Cancer.
ImmunoGen Inc.’s experimental ovarian cancer drug failed to meet the main goal of a late-stage study, driving the U.S. drug developer’s shares more than 40 percent lower.